Abstract - Recent FDA cleared/approved devices and biologics as well as current clinical trials in these types of products which promised improved vision by neurorecovery or at least slowing of the vision loss progression with neuroprotection including:  1) Spark Therapeutics LUXTURNA gene therapy; and 2) Okuvision OkuStim Electrical Stimulation Therapy.  In addition, retinal and cortical prosthetics have promised restored vision by substituting mechanisms in the visual system.  This presentation will provide a review of the actual results of these types of products and the challenges that

Abstract - Dr. Ron Schuchard will review the recent research and development for products that are marketed for treatment of vision loss. This review draws from his experiences as a vision rehabilitation researcher and as a FDA senior staff member.  Attendees will also be encouraged to ask about treatments for vision loss that are of interest to them.

Abstract - The distinction between stimulus chromaticity and perception of hue is critical for understanding color vision. A chromatic stimulus has spectral properties that characterize light entering the eye. The colors we experience, on the other hand, are perceptual constructs from neural processing within hierarchically organized cortical visual areas.